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ABSTRACT: 
Transplantation of human muscle precursor cells (hMPCs) is envisioned for the 
treatment of various muscle diseases. However, a feasible non-invasive tool to 
monitor cell survival, migration and integration into the host tissue is still missing. 
Methods: In this study, we designed an adenoviral delivery system to genetically 
modify hMPCs to express a signaling-deficient form of a human dopamine D2 
receptor (hD2R). The gene expression levels of the receptor were evaluated by 
Reverse Transcriptase Polymerase Chain Reaction (RTPCR) and infection 
efficiency was visualized by fluorescent microscopy. Viability, proliferation and 
differentiation capacity of the transduced cells were confirmed and their sustained 
myogenic phenotype was shown by flow cytometry analysis and fluorescent 
microscopy. 18F-Fallypride and 18F-FMISO, two well-established PET 
radioligands, were successfully synthesized and evaluated for their potential to 
image engineered hMPCs in a mouse model. Furthermore, biodistribution studies 
and autoradiography were also performed to determine the extent of signal 
specificity. Results: To address the feasibility of the presented approach for 
tracking of hMPCs in an in vivo model, we first evaluated the safety of the 
adenoviral gene-delivery, which showed no detrimental effects on the primary 
human cells. Specific binding of 18F-Fallypride to hD2R_hMPCs was 
demonstrated in vitro, as well as in vivo, by performing autoradiography, 
biodistribution and PET experiments, respectively. Furthermore, 18F-FMISO 
uptake was evaluated at different time-points after cell inoculation in vivo, showing 
high signal only at the early stages. Finally, histological assessment of the 
harvested tissues confirmed the sustained survival of the transplanted cells at 
different time-points with formation of muscle tissue at the site of injection. 
Conclusion: We here propose a signaling-deficient human D2R as a potent 
reporter for in vivo hMPCs PET tracking by 18F-Fallypride. This approach is a 
significant step forward towards a potential non-invasive tracking of hMPC_hD2R 
cells and bioengineered muscle tissues in the clinic. 
 
Key Words: human muscle precursor cells, dopamine 2 receptor, hypoxia, in vivo 
imaging, PET 
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INTRODUCTION 
To date, organ transplantation is the gold standard for rescuing damaged 
tissues. This method comes with a number of drawbacks such as dependence on 
donor organs and the high morbidity of immunosuppressive therapy. Regenerative 
medicine using autologous stem cells may offer an alternative approach for organ 
and tissue replacement, overcoming the known pitfalls(1-3). Tissue engineering, a 
major regenerative medicine component, follows the principles of cell 
transplantation, materials science, and engineering towards the development of 
biological substitutes that can restore and maintain normal function(4). Due to their 
regenerative capacity, MPCs are investigated for skeletal muscle tissue 
reconstruction and replacement(5). These adult stem cells reside on muscle fibers 
periphery, where they are activated after injury, proliferating, differentiating into 
myoblasts and later fusing to form new myofibers, thereby granting sufficient 
progeny for repetitive tissue repair(6). The majority of MPCs are committed to the 
myogenic lineage and are therefore the most suitable source for muscle 
engineering(7). Recent preclinical studies have shown that muscle reconstruction 
using MPCs is a promising and feasible therapy(8), however, the fate of the cells 
after implantation still needs to be further investigated. 
Currently, these issues are addressed by histological assessment, which has one 
major shortcoming: the invasiveness of biopsies and bioengineered muscle tissue 
destruction. Novel non-invasive imaging technologies are therefore needed. 
Molecular imaging is an emerging field, providing essential information about 
heterogeneous human disorders. While bioluminescence has very poor spatial 
resolution and magnetic resonance imaging lacks the high sensitivity of 
radionuclide-based tools, PET/CT is a system with both high resolution and high 
sensitivity(9). Although imaging reporter genes are available for fluorescence, 
bioluminescence and magnetic resonance imaging, only radionuclide-based 
reporter genes are currently investigated for use in patients(10-12). One such 
system is based on the D2R imaging using PET. Natively, the D2R expression is 
largely limited to the striata nigra brain region(13). A large number of specific and 
high-affinity D2R PET ligands are available, some of which have found routine 
application in the clinic(14). Thus, the PET imaging of exogenously added hD2R in 
cells injected in peripheral body regions would be an attractive method to track the 
hD2R in vivo. One potential shortcoming of this approach, however, is the possible 
induction of undesired biological effects by gene introduction and by alteration of 
intracellular signalling pathways. As binding of the D2R ligand would activate Gprotein- 
linked signalling pathway, a mutated rat receptor (D2R80A) has been 
reported, that uncouples ligand binding from intracellular signal 
transduction(15),(16). However, there are limits to the amount of signal production, 
as one receptor interacts with only one ligand molecule and can potentially be 
blocked by non-labelled endogenous ligands(17). 
Skeletal muscle cells are a key target for many stem cell and gene therapy 
applications. With PET imaging gaining increasing importance in regenerative 
medicine, it is of high interest to study transfected MPCs as cell types that could be 
used to restore muscle function. In this study, we investigated the possibility of 
using PET/CT imaging to non-invasively monitor implanted and genetically 
modified hMPCs_hD2R in a mouse model. Specifically, our main aim was to study 
the location, level of expression and survival duration of the engineered hMPCs 
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using hD2R as a reporter gene. The accomplishment of this goal would help to 
improve our understanding of the behaviour of hMPCs during in vivo differentiation. 
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MATERIALS AND METHODS 
 
Isolation and Expansion of hMPCs 
Human muscle biopsies from Musculus rectus abdominis were randomly collected 
after approval by the local institutional review board and after written informed 
consent of hospitalized patients undergoing abdominal surgery. All samples were 
processed according to established protocols(18). 
 
Adenoviral Design 
The AdEasy System (Stratagene(19)) was used for recombinant adenovirus 
construction. Briefly, we mutated phenylalanine 411 of the hD2R into alanine 
(F411A) to obtain a signalling-deficient hD2R that still binds ligands in a normal 
manner but will not activate intracellular signalling upon ligand binding(20). In 
detail, IRAUp969E0451D vector containing hD2R (ImaGenes) and pcDNA3 
plasmid containing monomer red fluorescent protein (m)RFP (Addgene) were 
purchased. The hD2R was subcloned into the pcDNA3.1 TOPO expressional 
vector (Invitrogen), which resulted in addition of C-terminal 6xHis and V5 tags. 
Next, the F411A point-mutation was introduced by site-directed-mutagenesis 
(Stratagene). The hD2R and mRFP sequences were then subcloned into the 
backbone of the pShuttle-cytomegalovirus vector (Addgene), ensuring a robust, 
constitutive expression. The final vector thus contained hD2R and RFP sequences, 
both running under two separate cytomegalovirus promoters. Successful cloning 
was validated by sequencing, while viral infection and gene expression were 
monitored by visualizing RFP and RTPCR, respectively. The transduced cells were 
expanded for 2 days after infection and were subcutaneously (s.c.) injected into 
nude mice. 
 
Cell Viability and Proliferation 
In all cases, cell numbers and viability were confirmed by trypan blue staining. To 
evaluate proliferation and viability of the infected cells at different time points, 
hMPCs were cultured for 6 days. The cell proliferation reagent WST-1 (Roche) was 
used according to manufacturer’s protocol. For further confirmation of cell viability, 
hMPCs were stained with 10 μM CellTrace Calcein green, AM (Life Technologies), 
30min, 37 °C. Viable cells were detected using a fluorescence microscope. All 
measurements were repeated at least three times and samples were analyzed in 
triplicates. 
 
Radiosynthesis of 18F-Fallypride 
The synthesis of 18F-Fallypride was accomplished in a one-step reaction 
according to a published procedure(21). The radiotracer was obtained in 
radiochemical purity >95% and specific activity ranged from 32-168 GBq/μmol. 
 
Radiosynthesis of 18F-FMISO 
18F-FMISO was obtained in a two-step reaction in analogy to a previously 
published method(22). The final formulated product was obtained in a decay 
corrected radiochemical yield ranging from 25-37%. Radiochemical purity was 
>95% and specific activities ranged from 34-190GBq/μmol. 
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In vitro 18F-Fallypride Uptake assay 
The experiment was performed in longitudinally truncated 24-well-plates testing 
two AV-hD2R constructs in three concentrations (500ng, 1μg, 2μg/well). 
Approximately 20`000 hMPCs/well were seeded and after 24h the cells were 
infected with the corresponding constructs for 2 days. The modified cells were 
incubated with 18F-Fallypride [1nM] for 15 min and scanned 26 min after start of 
incubation. The cells were imaged using small animal PET scanner. The scan 
duration was 45 min. All experiments were performed in triplicates. 
 
Animal Experimentation 
All animal experiments were approved by the local animal care committee. A total 
of 46 female, 8 week old nude mice (Charles River) were used for this study. The 
hMPCs were expanded to passage 3-4 for the in vivo experiments. Each sample 
contained 30x106 transduced hMPCs, which were gently mixed with 500μL 
collagen type I carrier (final concentration: 2mg/mL) (BD) and prepared for s.c. 
injection in the back of nude mice(23). Each animal received two bilateral s.c. 
injections (including control-collagen only injections). The engineered skeletal 
muscle tissues were harvested after 1, 2, and 4 weeks. 
 
Tracking of Bioengineered Muscle Tissues via PET/CT Imaging 
PET experiments were performed with a dedicated small animal PET/CT 
tomograph eXplore VISTA (General Electric), which uses the phoswich detector 
technology in a dual ring set-up(24). For 18F-Fallypride administration, mice were 
restrained and injected via a lateral tail vein with 4.38-26.25MBq (0.17-2.34nmol) of 
the radioligand. For blockage experiments, Haloperidol (1mg/kg) was injected. Ten 
minutes after radiotracer injection, animals were anesthetized with isoflurane in 
air/oxygen mixture, positioned and fixed on the bed of the camera. PET data were 
acquired to yield dynamic images with sufficient count statistics. Depth of 
anesthesia and body temperature were monitored and controlled according to a 
previously published protocol(25). In addition, respiratory frequency was controlled 
with 1025T monitoring system from SA Instruments (Stony Brook, NY). After the 
PET scan, animals recovered from anesthesia and were rescanned at a later time 
point with the next tracer. Raw data were reconstructed by 2D-OSEM algorithm 
and the obtained image data were evaluated by visual inspection and semiquantitative 
volume-of-interest(26) analysis using the dedicated software PMOD. 
 
Biodistribution Studies 
The subsequent post-mortem biodistribution assessment was performed 60 min 
post i.v. injection of 18F-Fallypride. Tracer uptake in engineered muscle tissue, 
striatum nigra, native muscle tissue, cerebellum and injected collagen was 
evaluated in a gamma-counter (CobraIIAuto-gamma, Canberra Packard, 
Groningen, Netherlands). 
 
Autoradiography 
Cryosections (20μm) of frozen samples were pre-incubated on ice for 12min in 
TRIS/HCl, 0.1% BSA, pH 7.4. Then, the slides were incubated with 18F-Fallypride 
[0.03nM] in the presence and absence of Haloperidol [10μM] as blocker for 60min. 
After air-drying the tissue slices were exposed to phosphorimager plates which 
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were analysed with Fuji BAS-5000 phosphorimager. 
 
Histological Assessment 
The harvested engineered muscle tissues were embedded in cryo-preservative 
(OCT embedding medium, Cell Path) immediately after isolation. Cryosections 
were prepared (10μm) and further processed. Haematoxylin and eosin (H&E) 
(Sigma) staining was performed according to the manufacturer’s protocol. 
 
Statistics 
For statistical analysis IBM SPSS v22.0 (SPSS Inc,) was used and graphs were 
drawn with GraphPad Prism v5.04 (GraphPad Software, Inc.). All data were 
analysed by Student’s t-tests or one-way ANOVA with Bonferroni or LSD post-hoc 
analysis (p<0.05 was considered significant). All presented data are expressed as 
means with corresponding standard error of the mean (±SEM). 
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RESULTS 
 
Viability, Proliferation and Differentiation Rates of Genetically Modified 
hMPC_hD2R 
The adenoviral construct containing hD2R (F411A) was generated and amplified 
for further use in hMPCs. Non-toxicity of the viral infection was visualized by a cell 
viability assay (calcein) (Fig.1A, green), where no significant differences between 
WT and hD2R-infected cells were detected. The transduction efficiency of ~25% 
infected cells was confirmed by fluorescent imaging, as the designed construct 
contained a red fluorophore, expressed under a separate cytomegalovirus 
promoter (Fig.1A, red). This construct allowed assessment of cell transduction 
efficiency prior to transplantation. Using a fiber formation assay(27), we evaluated 
the capability of hMPCs to form myofibers in vitro (Fig.1A, third row). Comparison 
between WT and hD2R-overexpressing cells (Supplemental Fig.1) did not reveal 
any significant difference in the number of nuclei per fiber (p=0.8629, WT: 
8.325±0.6818, n=83; hD2R: 8.184±0.4635, n=87), number of nuclei per highpower- 
field (WT: 230.6±14.34, n=10; hD2R: 216.9±10.71, n=10, p=0.4539) and the 
number of fibers per high-power-field (WT: 8.3±0.8699, n=10; hD2R: 8.4±0.5812, 
n=10, p=0.9249). The calculated overall fusion did not differ between infected and 
WT cells either (WT: 30.95±3.289, n=10; hD2R: 32.40±3.085, n=10, p=0.7512). 
Successful transduction was also confirmed by hD2R gene expression levels 
(Fig.1B, n=3x3, p=0.005). Furthermore, proliferation capacity of the WT and 
hD2Roverexpressing 
hMPCs was determined by cell proliferation assay over 3 days 
culturing following transduction, showing no significant variations between the 
different groups (Fig.1C, WT: 2.2173±0.364, n=6; hD2R: 2.0843±0314, n=6, 
p=0.787 at 3 days). 
 
Flow Cytometry and Immunocytochemistry Analysis of hMPC_hD2R 
Initially, the cells were analyzed by flow cytometry (Fig.2A), and in parallel by 
immunocytochemistry (Fig.2B) 2 days after infection, revealing a sustained muscle 
phenotype without significant alterations between the groups. 
 
In Vitro PET/CT Imaging of hMPC_hD2R Using 18F-Fallypride 
Before each experiment, the infection efficiency was assessed by fluorescent 
microscopy and positive cells were further processed for in vitro or in vivo studies. 
Initially, the capacity of the transduced hMPCs_hD2R to efficiently bind 18FFallypride 
was evaluated in vitro. When using the designed adenovirus, testing 3 
different concentrations of viral particles for tracer uptake, we observed a high 
binding affinity (Fig.3A). As expected, the cells infected with the highest non-toxic 
concentration showed the highest detectable PET signal (first row, 10x) and were 
thus used for further experiments. These data confirm the efficiency of the 
presented hD2R adenoviral construct for hMPCs genetic modification. 
 
In Vivo PET/CT Imaging of hMPC_hD2R Using 18F-Fallypride 
Encouraged by our in vitro results, we evaluated the capability of transduced 
hMPCs to specifically bind 18F-Fallypride in an established ex situ model for 
skeletal muscle tissue formation in vivo. The hMPC_hD2R showed high 
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standardized uptake value (SUV) after 1 week (SUV: 0.259±0.019, n=8). This 
signal decreased after two weeks (SUV: 0.169±0.019, n=8, p=0.005) and no 
significant difference to background was observed after 4 weeks (SUV: 
0.134±0.014, n=6, p<0.0001) (Fig.3B). Animals injected with collagen only did not 
show a significant radiotracer accumulation at any time (SUV: 0.115±0.011, n=10). 
Cerebellum brain region was used as negative control, showing negligible nonspecific 
uptake (SUV: 0.124±0.006, n=16). This was confirmed by VOI (26) 
analysis, where significantly higher signal-to-background ratio of at least 2.08 at 
the earliest time point was observed (Fig.3B). Biodistribution assessment also 
showed significant decrease in tracer uptake in engineered tissues over time 
(Fig.4A, n=4-16 per time point). Signal specificity was demonstrated in in vivo PET 
studies using haloperidol as D2R blocking agent; the striatum region was 
visualized as positive control (Fig.4B). Additionally, radioligand binding specificity 
was demonstrated in autoradiography studies, whereby hD2R-expressing tissues 
(including native controls) showed reduction of radioligand uptake after incubation 
with haloperidol (Fig.4C), confirming the in vivo data. 
 
PET Imaging of Hypoxia Using 18F-FMISO during Formation of 
Bioengineered Skeletal Muscle Tissue 
After successful tracking of the injected hMPC_hD2R, we were further interested in 
studying the oxygenation status of the cells after implantation. To address this we 
utilized 18F-FMISO, a PET radiotracer for visualizing hypoxic regions. One week 
after cell inoculation, a relatively high 18F-FMISO uptake was observed which 
decreased at later time points (Fig.5A). VOI analysis of the first week samples 
(SUV: 0.315±0.02, n=8) showed a mean signal change ratio of 1.6, compared to 
later time points (2wk: SUV: 0.189±0.019, n=8; 4wk: SUV: 0.205±0.009, n=6) and 
negative controls (cerebellum: SUV: 0.206±0.017, n=16; collagen: SUV: 
0.251±0.003, n=10 (Fig.5B)). 
 
Histological Assessment, Gene and Protein Analysis of the Harvested 
Tissues 
The relative protein expression of typical skeletal muscle protein markers 
(sarcomeric α-actinin, MyHC), vWf and hD2R were evaluated after tissue harvest 
by Western Blot (Fig.6A). Tibialis anterior (TA) and striatum nigra (SN) were used 
as controls. The protein expression levels of sarcomeric markers gradually 
increased in the bioengineered tissue samples (MyHC: 0.4211±0.033, n=4 (1wk); 
2.1915±0.407, n=6 (2wk); 3.0734±0.72, n=8 (4wk), p=0.012, respectively; α- 
actinin: 0.4065±0.111, n=4 (1wk); 0.6734±0.113, n=6 (2wk); 1.2696±0.315, n=8 
(4wk), p=0.043, respectively), corresponding to the expected timeline of muscle 
fiber formation (Fig.6A). The relative hD2R protein expression decreased steadily 
over time (2.4072±0.608, n=3 (1wk); 1.5881±0.25, n=6 (2wk); 1.0394±0.294, n=12 
(4wk), p=0.031, respectively) (Fig.6A), concomitant with the observed decrease of 
18F-Fallypride uptake (Fig.3B). The decrease in 18F-FMISO uptake over time 
coincided with an increase in vWf protein levels (endothelial cell marker, n=4) 
(Fig.6A), as well as with a rising vascular endothelial growth factor (VEGF-A) gene 
expression (Supplemetal Fig.2B, n=9) in the bioengineered muscle tissues. 
Although hD2R protein levels were decreasing over time, the corresponding gene 
expression levels were increasing (Supplemental Fig.2B). The gradual decrease in 
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size due to collagen remodeling and myofiber formation has previously been 
reported(23) (Supplemental Fig.2A). Histological analysis revealed successful 
myofiber formation in the harvested tissues and could illustrate the individual cells 
of the samples at week 1 and the myotube formation at week 2 and 4 (Fig.6B). 
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DISCUSSION 
 
Transplantation of MPCs has been considered as a treatment option for 
genetic and acquired muscle disorders(23, 28) and provides a prospect to 
reestablish damaged muscle function in patients with muscle degeneration(29). 
Various research groups demonstrated the formation of muscle tissue after cellular 
inoculation(30). However, the long-term non-invasive tracking of bioengineered 
muscle tissue has not been addressed so far. 
The need to develop a system combining the use of well-established PET 
probes and the engineering of a novel vector for expression of the hD2R in hMPCs 
has prompted our research towards non-invasive visualization of a cell therapy for 
application in skeletal muscle bioengineering. The generation of a vector coding for 
a signaling-deficient hD2R was an important milestone as redundant cell-signaling 
is a major issue in gene therapies. 
In this study, we describe a method for metabolic imaging and tracking of hMPCs 
using PET/CT, thereby illustrating their exact position and the oxygenation state of 
the newly formed skeletal muscle tissue over time. The results of our studies 
indicated that: 1) the signaling-deficient hD2R could be efficiently introduced into 
primary hMPCs, 2) no detrimental effects on cell viability and differentiation were 
detected, 3) myogenic marker gene expression was unaltered, 4) the receptor was 
traceable with high specificity using 18F-Fallypride both in cells in vitro as well as 
after injection in vivo and 5) receptor expression in the engineered tissues could be 
validated by autoradiography. We found that the capacity to track the 
hD2R_hMPCs is excellent in the first week and declines later on. Interestingly, 
while mRNA expression of hD2R remained high, its protein levels steadily 
declined. This indicates that the ectopically expressed hD2R is either post 
translationally modified and/or internalized upon constitutive expression and 
ultimately degraded during the process of final differentiation to myofibers. Our 
data showed that by using a high-affinity PET ligand and a mutated hD2R we were 
able to provide important information on localization, survival and metabolic 
features for the early phase after cell injection. 
A general problem in tissue engineering approaches is the increased 
oxygen demand and lack of initial vascularization during the early phases of tissue 
formation, leading to central necrosis(31). Any engineered tissue larger than 0.3 
cm3 requires rapid vascularization to guarantee survival of cells located within the 
core of the construct. Vascularization of bioengineered tissue is therefore a bottleneck. 
Hypoxia, which is inversely proportional to the degree of vascularization can 
be analysed by invasive and non-invasive methods in tissues. The oxygenation 
status of cells and tissues can be determined by invasive pO2-measurements 
using polarographic needle electrodes or with fiber-optic probes(32-34). Noninvasive 
methods include the use of bio-reductive chemical markers, such as 2- 
nitroimidazoles(35). They form adducts under hypoxic conditions and are 
irreversibly bound in hypoxic cells. 18F-FMISO is the most widely used PET 
radioligand for imaging hypoxia in humans(36-38). 
In our study with 18F-FMISO, we detected metabolically active 
bioengineered tissues with low oxygen levels, i.e. where reductive reactions 
dominate due to low oxygen supply or high oxygen consumption, typical for the 
early stages of cell-to-myofiber formation. It has been shown that the level of 
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oxygenation is influenced by the degree of vascularization and by the metabolic 
consumption of oxygen by engineered tissue(39). Concomitant with our in vivo 
observations, increased VEGF release in a hypoxic environment has been shown 
to lead to enhanced differentiation(40). Histological analysis confirmed the cell-
tomyofiber 
transition, correlating with normalized vascularization levels. In line with 
these observations, using 18F-FMISO for hypoxia imaging of bioengineered 
constructs seems to be a feasible method. 
 
CONCLUSION 
Knowledge of the fate of the inoculated primary hMPCs is a prerequisite for 
future clinical implementation of this cell therapy. Combining the recent 
developments in designing robust vectors and novel highly-specific PET imaging 
probes, we were able to offer an elegant solution, obviating the need for a 
destructive tissue biopsy. Our study marks a significant step forward towards the 
non-invasive tracking of hMPC_hD2R cells and bioengineered muscle tissues in 
the clinic using PET. 
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18 
Figure Legends 
 
Figure 1. hD2R adenoviral infection did not show adverse effects on hMPC. 
The adenoviral transduction of hMPCs with hD2R did not affect the cell viability (A, 
calcein assay, first row, green). Transduction efficiency was shown by fluorescence 
microscopy (A, second row, red). The ability to form fibers (27) was also not 
affected by the virus (A; third row). The hD2R gene expression was evaluated (B). 
Proliferation rate did not differ between WT non-infected and infected hMPCs (C). 
All measurements were performed in duplicates from at least 3 different biopsies. 
(Student’s t-test, *p<0.05). CaAM: calcein AM; FFA: fiber-formation-assay; RFP: 
red-fluorescent-protein; WT: wild type 
 
Figure 2. Adenoviral infection with hD2R did not change the well-defined 
hMPC phenotype. The hMPCs were analyzed by flow cytometry (A). Expression 
of typical muscle markers (green) in the cells expressing hD2R (red) was further 
confirmed by immunocytochemistry. Nuclei are shown in blue (B). Scale bar: 
25μm. (Student’s t-test, *p<0.05, n=4 biopsies). 
 
Figure 3. Tracking of hMPCs and engineered muscle tissue via PET/CT using 
18F-Fallypride in vitro and in vivo. 18F-Fallypride uptake in hMPC_hD2R was 
detected at different adenoviral hD2R transduction levels (A). In vivo PET/CT 
imaging visualized specific tracer uptake in bioengineered tissues over time and 
VOI analysis illustrated gradual decrease in signal after 1wk (B, n=6-8). SUV: 
standardized uptake value, VOI: volume-of-interest. 
 
Figure 4. Specificity of 18F-Fallypride signal. Significant enhancement of 
18FFallypride 
uptake in engineered hMPC_hD2R tissue, compared to collagen and 
control muscle was observed in a biodistribution study (A, n=4-16). Tracer 
specificity was evaluated after blockage experiment with Haloperidol (B). 
Autoradiography showed specific tracer binding (C, lane 1). Blockage was 
performed with Haloperidol (lane 2) and mouse muscle and rat brain sections were 
used as negative and positive controls, respectively. Images were averaged from 
60 – 120 min. Arrows indicate hMPCs injection site. (one-way ANOVA with 
Bonferroni post-hoc analysis, *p<0.05), SUV: standardized uptake value 
 
Figure 5. Hypoxia PET/CT monitoring with 18F-FMISO during formation of 
bioengineered muscle tissues. The redox state of the forming tissues was 
illustrated with 18F-FMISO [injected activity: 0.49-5.86nmol, 14.86-35.83MBq] (A) 
and VOIs signal was calculated for 3 different time points (B). Images were 
averaged from 90–110 min. Arrows indicate hMPCs injection sites. 
 
Figure 6. Protein expression levels were evaluated by Western Blot (A): vWf, 
MyHC, sarcomeric α-actinin and hD2R expression changes were visualized 
graphically. H&E staining revealed increasing fiber formation capacity over 
time (B). Tibialis anterior (TA) was used as a control. Scale bar: 100μm 
(one-way ANOVA with Bonferroni or LSD post-hoc analysis, *p<0.05) 
 






